Honz Pharmaceutical Co., Ltd. (SHE:300086)
China · Delayed Price · Currency is CNY 7.40
+0.18 (2.49%)
Apr 30, 2026, 3:04 PM CST
Honz Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 466.12 | 447.15 | 703.1 | 504.13 | 806.99 |
Other Revenue | - | 25.67 | 36.47 | 31.61 | 29.57 |
| 466.12 | 472.82 | 739.57 | 535.75 | 836.57 | |
Revenue Growth (YoY) | -1.42% | -36.07% | 38.05% | -35.96% | -9.23% |
Cost of Revenue | 213.48 | 225.36 | 298.27 | 269.35 | 418.41 |
Gross Profit | 252.65 | 247.46 | 441.3 | 266.4 | 418.16 |
Selling, General & Admin | 386.27 | 379.33 | 352.59 | 360.73 | 384.03 |
Research & Development | 19.1 | 19.05 | 18.68 | 28.44 | 14.7 |
Other Operating Expenses | 7.31 | 9.79 | 12.71 | 10.88 | 11.27 |
Operating Expenses | 412.69 | 404.18 | 386.46 | 413.05 | 423.52 |
Operating Income | -160.04 | -156.72 | 54.84 | -146.65 | -5.37 |
Interest Expense | - | -21.07 | -25.3 | -27.4 | -18.74 |
Interest & Investment Income | 1.45 | 17.52 | 2.86 | 2.8 | 56.94 |
Earnings From Equity Investments | - | - | - | -0.21 | - |
Currency Exchange Gain (Loss) | - | 0.01 | 0.01 | -0.21 | 0.11 |
Other Non Operating Income (Expenses) | -8.17 | -5.82 | -1.21 | 3.27 | -5.49 |
EBT Excluding Unusual Items | -166.77 | -166.08 | 31.2 | -168.41 | 27.46 |
Impairment of Goodwill | - | -6.55 | - | - | -3.4 |
Gain (Loss) on Sale of Investments | -37.04 | -18.14 | -11.6 | -23.62 | -5.51 |
Gain (Loss) on Sale of Assets | 0.47 | -0.23 | 0.72 | 0.1 | 0.07 |
Asset Writedown | -56.14 | -38.7 | -2.12 | -28.55 | -0.39 |
Legal Settlements | - | - | - | - | -0.05 |
Other Unusual Items | - | -2.27 | 5.24 | -1.04 | 2.19 |
Pretax Income | -259.47 | -231.97 | 23.45 | -221.52 | 20.35 |
Income Tax Expense | -25.44 | -7.54 | 18.28 | -23.57 | 9.78 |
Earnings From Continuing Operations | -234.03 | -224.43 | 5.17 | -197.95 | 10.57 |
Minority Interest in Earnings | 3.89 | 8.22 | 6.36 | 10.37 | 0.42 |
Net Income | -230.14 | -216.21 | 11.53 | -187.58 | 10.99 |
Net Income to Common | -230.14 | -216.21 | 11.53 | -187.58 | 10.99 |
Net Income Growth | - | - | - | - | 17.65% |
Shares Outstanding (Basic) | 455 | 456 | 450 | 450 | 450 |
Shares Outstanding (Diluted) | 455 | 456 | 450 | 450 | 450 |
Shares Change (YoY) | -0.29% | 1.34% | 0.10% | -0.08% | 0.29% |
EPS (Basic) | -0.51 | -0.47 | 0.03 | -0.42 | 0.02 |
EPS (Diluted) | -0.51 | -0.47 | 0.03 | -0.42 | 0.02 |
EPS Growth | - | - | - | - | 17.31% |
Free Cash Flow | 29.12 | -21.04 | -66.87 | -29.57 | -208.64 |
Free Cash Flow Per Share | 0.06 | -0.05 | -0.15 | -0.07 | -0.46 |
Gross Margin | 54.20% | 52.34% | 59.67% | 49.72% | 49.98% |
Operating Margin | -34.34% | -33.15% | 7.41% | -27.37% | -0.64% |
Profit Margin | -49.37% | -45.73% | 1.56% | -35.01% | 1.31% |
Free Cash Flow Margin | 6.25% | -4.45% | -9.04% | -5.52% | -24.94% |
EBITDA | -93.17 | -94.15 | 132.27 | -96.41 | 33.61 |
EBITDA Margin | -19.99% | -19.91% | 17.88% | -18.00% | 4.02% |
D&A For EBITDA | 66.88 | 62.57 | 77.43 | 50.25 | 38.98 |
EBIT | -160.04 | -156.72 | 54.84 | -146.65 | -5.37 |
EBIT Margin | -34.34% | -33.15% | 7.41% | -27.37% | -0.64% |
Effective Tax Rate | - | - | 77.95% | - | 48.06% |
Revenue as Reported | - | 472.82 | 739.57 | 535.75 | 836.57 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.